Thomas Buchanan, MD
Neurology · Salt Lake City, UTNPI 1710162227
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 366 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,231, 5.3 times the $421 reported in 2019.
Across 366 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$641
- UCB, Inc.$589
- EMD Serono, Inc.$530
- Pfizer$494
- Novartis$312
- Argenx US, Inc.$292
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,241100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,241 in reported general payments places this provider in the 70th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 20 | $184,036 |
| CopaxoneGlatiramer Acetate | 13 | $84,691 |
| XcopriCenobamate | 64 | $77,958 |
| Nurtec OdtRimegepant Sulfate | 52 | $73,333 |
| NuplazidPimavanserin Tartrate | 17 | $71,696 |
| AptiomEslicarbazepine Acetate | 17 | $44,403 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $24,078 |
| EliquisApixaban | 24 | $19,708 |
| Emgality PenGalcanezumab-Gnlm | 19 | $19,707 |
| BotoxOnabotulinumtoxina | 15 | $19,305 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $16,693 |
| Dalfampridine ErDalfampridine | 42 | $16,480 |
| NayzilamMidazolam | 15 | $14,679 |
| KeppraLevetiracetam | 14 | $13,242 |
| VimpatLacosamide | 12 | $12,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $494 | $93,04276 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $177 | $84,69113 claims |
| SK Life Science, Inc.Xcopri | $110 | $77,95864 claims |
| Acadia Pharmaceuticals IncNuplazid | $35 | $71,69617 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $13 | $44,40317 claims |
| UCB, Inc.Nayzilam, Vimpat | $589 | $27,48127 claims |
| AbbVieBotox | $641 | $19,30515 claims |
| Lilly USA, LLCReyvow | $148 | $9,61213 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $13 | $2,39723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 neurology providers in Utah.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.